A method of determining one or more probabilities of respective classifications of a large intestine neoplasm in an individual, said method comprising assessing the methylation status of a DNA region selected from: (i) the region, including 2kb upstream of the transcription start site, defined by at least one of Hg19 coordinates chr12:24962958..25102393; and (ii) the gene region, including 2kb upstream of BCAT1 and optionally further comprising assessing the methylation status of at least one DNA region selected from: (i) the region, including 2kb upstream of the transcription start site, defined by at least one of Hg19 coordinates: chr7:50344378...50472798 chr6:391739..411443; chr12:52400748..52409671; and chr6:163834097..163834982; or (ii) the gene region, including 2kb upstream of at least one of: IKZF1 IRF4 GRASP and CAHM in a blood-derived sample from said individual, wherein a level of methylation of at least one of the DNA regions of group (i) and/or (ii) relative to corresponding measured levels of methylation from a population of individuals with known neoplastic categories of corresponding large intestine neoplasms is used to determine one or more probabilities of respective classifications of said large intestine neoplasm of said individual into one or more neoplastic categories selected from adenoma, stage I, stage II, stage III, and stage IV categories or into one or more aggregates of fewer than five of said neoplastic categories. (i) the region, including 2kb upstream of the transcription start site, defined by at least one of Hg19 coordinates chr12:24962958..25102393; and (ii) the gene region, including 2kb upstream of BCAT1 and optionally further comprising assessing the methylation status of at least one DNA region selected from: (i) the region, including 2kb upstream of the transcription start site, defined by at least one of Hg19 coordinates: chr7:50344378...50472798 chr6:391739..411443; chr12:52400748..52409671; and chr6:163834097..163834982; or (ii) the gene region, including 2kb upstream of at least one of: IKZF1 IRF4 GRASP and CAHM in a blood-derived sample from said individual, wherein a level of methylation of at least one of the DNA regions of group (i) and/or (ii) relative to corresponding measured levels of methylation from a population of individuals with known neoplastic categories of corresponding large intestine neoplasms is used to determine one or more probabilities of respective classifications of said large intestine neoplasm of said individual into one or more neoplastic categories selected from adenoma, stage I, stage II, stage III, and stage IV categories or into one or more aggregates of fewer than five of said neoplastic categories. (i) the region, including 2kb upstream of the transcription start site, defined by at least one of Hg19 coordinates: chr7:50344378...50472798 chr6:391739..411443; chr12:52400748..52409671; and chr6:163834097..163834982; or chr7:50344378...50472798 chr6:391739..411443; chr12:52400748..52409671; and chr6:163834097..163834982; or (ii) the gene region, including 2kb upstream of at least one of: IKZF1 IRF4 GRASP and CAHM in a blood-derived sample from said individual, wherein a level of methylation of at least one of the DNA regions of group (i) and/or (ii) relative to corresponding measured levels of methylation from a population of individuals with known neoplastic categories of corresponding large intestine neoplasms is used to determine one or more probabilities of respective classifications of said large intestine neoplasm of said individual into one or more neoplastic categories selected from adenoma, stage I, stage II, stage III, and stage IV categories or into one or more aggregates of fewer than five of said neoplastic categories.